Dosimetry of Organs at Risk for Lutathera Treatment Between Meningioma and Neuroendocrine Tumor (LUDOMET)
To Compare the Dosimetry of Organs at Risk in Patients Treated With Lutathera® for Meningioma Versus Neuroendocrine Tumor (NET).
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.
研究概览
地位
地位
详细说明
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.Thus, the aim of the study will be to determine the dosimetry of organs at risk in patients treated with Lutathera® for meningioma and for a neuroendocrine tumor (NET).
研究类型
研究类型
注册 (估计的)
注册
联系人和位置
学习联系方式
学习联系方式
- 姓名:Antoine VERGER, MD,PhD
- 电话号码:+33 0383155567
- 邮箱:a.verger@chru-nancy.fr
研究联系人备份
- 姓名:Véronique Roch, MSc
- 电话号码:0383154276
- 邮箱:v.roch@chru-nancy.fr
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
SPECT scans recorded for each patient who received at least one cycle of Lutathera® treatment for a meningioma or a NET will be analyzed.
描述
Inclusion Criteria:
- Patients who have received at least one course of Lutathera® treatment for a meningioma or a NET
Exclusion Criteria:
- Patient who has objected to the collection of their data
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:RETROSPECTIVE
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To compare the dosimetry of organs at risk in patients treated with Lutathera® for meningioma versus neuroendocrine tumor
大体时间:Day 1
|
Calculation of dosimetry for organs at risk (kidney, spleen, liver, bone marrow) in the two patient populations treated with Lutathera® |
Day 1
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 months after the last Lutathera® cycle
大体时间:3 months
|
Biology results |
3 months
|
|
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 12 months after the last Lutathera® cycle
大体时间:12 months
|
Biology results |
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.